Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies
LONDON, May 29, 2014 /PRNewswire/ --
Osteoporosis drugs - new study showing you trends, R&D progress, and predicted revenues
Where's the osteoporosis drugs market heading? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.
Our 217-page report provides 132 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market.
Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT, PESTEL and Porter's Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
- Dr. Karl Grindulis, Consultant Rheumatologist, Sandwell General Hospital, West Bromwich, UK
- Dr. Matthew Drake, Consultant in the Department of Medicine, Division of Endocrinology, Mayo Clinic Rochester, Minnesota, US
Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you see forecasts to 2024 for these three submarkets and their respective segments:
• Antiresorptive Drugs
- Bisphosphonates
- Selective Oestrogen Receptor Modulators (SERMs)
- RANKL Antibodies
- Cathepsin K Inhibitors
- Other antiresorptive drugs
• Anabolic Drugs
- Human Recombinant Parathyroid Hormones
- Anti-Sclerostin monoclonal antibodies
• Other osteoporosis treatments
Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
See revenue forecasts for products
How will leading drugs perform to 2024 at world level? Our study forecasts sales of 10 products, including these:
• Forteo
• Evista
• Prolia
• Actonel/Atelvia
• Fosamax
• Reclast/Aclasta
• Boniva
Our study also provides sales forecasts to 2024 for the following drugs which are currently in development:
• Duavee
• Odanacatib
• Romosozumab
Discover how high revenues can go. You will see what's happening, understanding trends, challenges and opportunities.
Our analysis also breaks the main world forecast into geographical markets.
What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 12 national markets to 2024:
• US
• Japan
• China
• Germany
• France
• UK
• Italy
• Spain
• India
• Brazil
• Russia
• South Korea
• Rest of the World
There will be growth in established pharma markets and in developing countries. Our analyses show that India, Brazil, China, Russia and South Korea in particular, will continue to achieve high revenue growth to 2024. Developments worldwide in product approval and pricing will influence the market.
Leading companies and potential for market growth
Overall world revenue for osteoporosis drugs will reach $8.36bn in 2014, our work forecasts. We predict steady revenue growth from 2014 to 2024. Rising demand for osteoporosis drugs, expanding healthcare coverage, and the success of biological drugs will increase sales to 2024.
Our work shows you what organisations hold greatest potential. See profiles of 8 leading companies, including these:
• Eli Lilly
• Amgen
• GSK
• Merck
• Pfizer
• Novartis
• Sanofi
• Actavis
In general, a company profile gives you the following information:
• Revenue forecast for osteoporosis drugs from 2014 to 2024
• Discussion of a company's activities and outlook
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
What issues will affect the osteoporosis drugs industry?
Our new report discusses issues and events affecting the osteoporosis drugs market. You will find discussions, including qualitative analyses:
• A global aging population
• Increasing awareness of osteoporosis and bone health education
• Expected launch of innovative therapies
• Increasing funds for R&D and clinical development
• Patent expirations of leading drugs
• Increasing generic competition
• Stringent regulation in key national markets
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How the Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies report helps you
In summary, our 217-page report gives you the following knowledge:
• Revenues forecast to 2024 for the world osteoporosis drugs market, 3 submarkets and 7 distinctive segments - discover the industry's prospects, finding promising places for investments and revenues
• Revenue forecasts to 2024 for the leading 12 national markets - US, Japan, China, Germany, France, UK, Italy, Spain, India, Brazil, Russia, South Korea and Rest of the World
• Assessment of 8 leading companies - hear about products, results and strategies including revenue forecasts for osteoporosis drugs to 2024
• Predicted revenues of 7 leading marketed osteoporosis drugs and 3 pipeline drugs to 2024 - see potentials of top products
• Review of R&D pipelines - investigate developmental trends and progress
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• View opinions from our survey, seeing interviews with authorities
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain's study is for everybody needing commercial analyses for the osteoporosis drugs market and leading companies. You find data, trends and predictions. Please order our report now.
To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel : +44 (0) 20 7336 6100
Companies Listed in this report:
AbiogenPharma S.p.A
Ablynx
Actavis
Ahn-Gook Pharmaceutical
Ajinomoto Pharmaceuticals Co
Almirall
Amgen
Anda, Inc
Apotex Inc
Asahi Kasei
Astellas
AstraZeneca
Aurobindo Pharma
Aventis
Aventis Pharma Ltd
Azelon Pharmaceuticals
Banner Pharmacaps
Banyu
Barr Pharmaceuticals
Bayer
Celltech
Chugai Pharmaceutical Co. Ltd
Ciba Specialty Chemicals
Ciba-Geigy
Daiichi Sankyo
Dow Jones Industrial Average
EffRx Pharmaceuticals
Eisai Co., Ltd
Eli Lilly and Company
Eli Lilly Japan K.K
Fermenta Biotech
Glaxo Wellcome plc
GlaxoSmithKline (GSK)
Hoffmann-La Roche (Roche)
Jiangsu Hengrui Medicine Co., Ltd
LaboratoriosAtral
Lacer S.A
Ligand Pharmaceuticals
Medis
Merck & Co
Merck Frosst
Merck Sharp & Dohme
Nordic Bioscience
Novartis
Novartis International AG
NPS Pharmaceuticals
Nycomed
Ono Pharma
OsteoGeneX
Pfizer, Inc
Procter & Gamble (P&G)
Qingdao Chia Tai Haier Pharmaceutical Co., Ltd
QS Pharma
Radius Health Inc.
Roche
Sandoz
Sanofi Pasteur
Sanofi S.A
Sanofi-Aventis
Sanofi-Synthélabo
Searle
Servier
SmithKline Beecham plc
Sumitomo Pharma
Taisho
Taisho Pharmaceutical Holdings
Takeda
Takeda Pharmaceutical Co., Ltd
Tarsa
Teva Pharmaceutical Industries
UCB
Unigene Laboratories
Warner Chilcott
Wyeth Pharmaceuticals
Zosano Pharma
Other Organisations Mentioned in this Report
American Society for Bone and Mineral Research (ASBMR)
British National Formulary (BNF)
Derwent World Patent Index
Duke University Medical Centre
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
German Federal Joint Committee
Harvard College
Health Canada
International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
International Osteoporosis Foundation (IOF)
Japanese Ministry of Health, Labour, and Welfare
Mayo Clinic
Ministry of Civil Affairs of China
National Health Service (NHS)
National Institute for Health and Care Excellence (NICE)
National Osteoporosis Foundation (NOF)
Pedriatic Investigation Plan (PIP)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Plaintiffs' Steering Committee
Sandwell General Hospital
The Committee for Medicinal Products for Human Use (CHMP)
The Committee to Evaluate Drugs (CED)
The United Nations
US Preventive Services Task Force
Washington University
World Bank
World Health Organization (WHO)
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
Share this article